SCHEMBL6404563

SCHEMBL6404563

O=P(O)(O)c1cc(O)ccc1C(O)(O)CCc1cccc(O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.41
DRD1 P21728 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
GRM2 Q14416 1/20 0.38
GRM3 Q14832 1/20 0.38
IDO1 P14902 1/20 0.38
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
OPRK1 P41145 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
NR1H3 Q13133 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6395652 0.92 MGLL (0.40) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6398625 0.89 DRD2 (0.41) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6395042 0.87 ESR1 (0.37) TAAR1
SCHEMBL6396486 0.86 GGPS1 (0.40) DRD2DRD1TAAR1ENPP2DRD4
SCHEMBL6398147 0.82 DRD2 (0.39) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6402094 0.82 MGLL (0.40) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL6396083 0.81 DRD2 (0.38) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6404559 0.81 IDO1 (0.39) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6396873 0.80 DRD2 (0.40) DRD2DRD1TAAR1GRM2GRM3
SCHEMBL6396954 0.80 IGF1R (0.37) CHRM2CHRM1CHRM3MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 DRD2 1797/4885DRD1 1654/4885TAAR1 2528/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 DRD2 1795/4885DRD1 1781/4885TAAR1 2659/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 DRD2 1797/4885DRD1 1654/4885TAAR1 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.